Biovertis

Biovertis was a Vienna-based biotechnology company dedicated to developing innovative anti-infective drugs to combat antibiotic-resistant bacteria. The company's primary focus was on Gram-positive pathogens, specifically targeting methicillin-resistant Staphylococcus aureus (MRSA) through the inhibition of essential bacterial enzymes. Its lead candidate, BV-2001, was a small molecule peptide deformylase inhibitor that reached early clinical development. Biovertis utilized a target-based drug discovery platform to identify novel chemical classes with the potential to overcome existing resistance mechanisms. The company was backed by a consortium of prominent venture capital firms, including TVM Capital, 3i, and Gilde Healthcare. In 2006, Biovertis was acquired by Trigen AG, a move that integrated its anti-infective pipeline into Trigen's broader development portfolio.